LGALS3 and Alzheimer disease: In neurodegenerative conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), Lgals3 has been established as a biomarker in serum, plasma, and/or cerebrospinal fluid (CSF) [33].